Clinical case: the experience of using acetylsalicylic acid, fosinopril and diltiazem in the therapy of a patient with cardiovascular pathology

Abstract

The article briefly describes the inhibitor of angiotensin converting enzyme (ACEI) - fosinopril, calcium channel blocker - diltiazem and antiplatelet agent- acetylsalicylic acid (ASA). The mechanism of their action and possible side effects are given. The authors of the article described in detail the antihypertensive drug from the group ACEI - fosinopril, antiplatelet agent - ASA and non-hydropyridine calcium channel blocker - diltiazem. The results of multicenter randomized trials of ASA, fosinopril in patients with arterial hypertension, ischemic heart disease, nephropathy and heart failure are presented. The article presents a clinical example that demonstrates the selection of the optimal drugs for the treatment of the combined pathology of the heart and kidneys, and also provides an evidence base for the efficacy and safety of fosinopril and ASA preparations. Presented drugs (ASA, fosinopril, diltiazem) are highly effective in all categories of patients with CVD and can be recommended for wider clinical use.

Keywords

• angiotensin-converting enzyme inhibitor
• fosinopril
• calcium channel blocker
• diltiazem
• antiplatelet agents
• acetylsalicylic acid
• arterial hypertension
• nephropathy
• heart failure
• myocardial infarction